Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528120424/en/
![Milan Kalawadia (Photo: Business Wire)](https://mms.businesswire.com/media/20240528120424/en/2142713/4/Milan-pic.jpg)
“I am excited to start this next chapter in my journey at Dr. Reddy’s,” says
During his 18-year tenure at Dr. Reddy’s, Milan has held various positions of increasing responsibility beginning in 2006 with roles in Finance, Investor Relations, Corporate/Business Development, Marketing and Head of NAG OTC and SRx divisions. Most recently, Milan served as Chief Commercial Officer, responsible for the customer-facing and commercialization operations for the three main verticals of the core NA business: retail Rx, hospital/institutional injectable, and private label OTC. Milan led the early efforts to develop strategies for the Biosimilars and the Self-care & Wellness business units in the US. He played a critical role in driving various new growth initiatives including the acquisition of OTC brands; the development of our e-commerce presence on Amazon; and engaging with alternate channel partners.
“During the last three years, Milan’s efforts as Chief Commercial Officer were instrumental in driving
Milan holds a Bachelor of Science degree in Management Science and Information Systems from
RDY-0524-corp
About Dr. Reddy’s: Dr. Reddy’s
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528120424/en/
INVESTOR RELATIONS
RICHAPERIWAL@drreddys.com
MEDIA RELATIONS
USHAIYER@DRREDDYS.COM
Source: